Vosol Hc

Infection, Communicable Diseases, Urinary Bladder + 2 more

Treatment

5 FDA approvals

6 Active Studies for Vosol Hc

What is Vosol Hc

Acetic acid

The Generic name of this drug

Treatment Summary

Hydrocortisone, also known as cortisol, is a hormone produced by the adrenal cortex. It is used to treat various conditions related to inflammation, the immune system, and cancer. Hydrocortisone was first discovered in the 1930s and was approved by the FDA in 1952.

Acetic Acid

is the brand name

image of different drug pills on a surface

Vosol Hc Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Acetic Acid

Acetic acid

1979

33

Approved as Treatment by the FDA

Acetic acid, otherwise called Acetic Acid, is approved by the FDA for 5 uses which include External ear infection NOS and Urinary Bladder .

External ear infection NOS

Used to treat External ear infection NOS in combination with Acetic acid

Urinary Bladder

Urethral Catheters

Infection

Communicable Diseases

Used to treat External ear infection NOS in combination with Acetic acid

Effectiveness

How Vosol Hc Affects Patients

Hydrocortisone works by attaching to a particular receptor in the body, which helps stop inflammation and reduce symptoms. It is considered to be a safe medication, and its effects usually last for a moderate amount of time. If a patient experiences irritation or sensitivity to the drug, they should stop taking it.

How Vosol Hc works in the body

Corticosteroids help reduce inflammation and swelling in the body. These drugs work by targeting certain genes that control inflammation. Corticosteroids prevent neutrophils from dying and slow down the production of molecules that cause inflammation. Low doses have an anti-inflammatory effect, but high doses can weaken your immune system. In addition, high doses of corticosteroids can raise sodium levels and lower potassium levels in the body.

When to interrupt dosage

The prescribed dosage of Vosol Hc is contingent upon the determined disorder, including Ophthalmia, Sympathetic, Drug Allergy and Sarcoidosis. The measure of dosage is contingent upon the technique of delivery (e.g. Topical or Auricular (otic)) specified in the table below.

Condition

Dosage

Administration

Communicable Diseases

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Infection

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Urinary Bladder

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Otitis Externa

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Urethral Catheters

, 20.75 mg/mL, 20.65 mg/mL, 2.5 mg/mL, 24.1 mg/mL, 0.02 mL/mL, 0.009 mg/mg, 20.8 mg/mL, 25.0 mg/mL, 2.0 mg/mL, 0.02 mg/mL, 1.5 %, 0.9 mg/mL, 20.0 mg/mL, 0.0092 mg/mg, 0.1 mg/mL, 10.81 mg/mL, 10.8 mg/mL, 8.11 mg/mL, 8.846 mg/mL, 5.41 mg/mL, 6.64 mg/mL, 5.28 mg/mL, 6.635 mg/mL, 36.0 mg/mL, 6.31 mg/mL, 5.4 mg/mL, 8.8 mg/mL, 8.85 mg/mL, 6.82 mg/mL, 6.305 mg/mL, 6.756 mg/mL, 8.1 mg/mL, 8.9 mg/mL, 8.847 mg/mL, 6.6349 mg/mL, 6.3053 mg/mL, 8.107 mg/mL, 0.004 meq/mL, 15.0 mg/mL

Solution, , Solution - Auricular (otic), Auricular (otic), Irrigation, Irrigant - Irrigation, Irrigant, Vaginal, Jelly, Jelly - Vaginal, Liquid, Hemodialysis, Solution - Hemodialysis, Liquid - Hemodialysis, Solution / drops, Topical, Gel - Topical, Gel - Vaginal, Gel, Solution / drops - Auricular (otic), Solution - Topical, Liquid - Topical

Warnings

Vosol Hc has fourteen contraindications and should not be used concurrently with the conditions outlined in the following table.

Vosol Hc Contraindications

Condition

Risk Level

Notes

use during transurethral surgical procedures

Do Not Combine

Tympanic Membrane Perforation

Do Not Combine

There are 18 known major drug interactions with Vosol Hc.

Common Vosol Hc Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Acetic acid.

Typhoid vaccine

Minor

The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Acetic acid.

(R)-warfarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with (R)-warfarin.

(S)-Warfarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with (S)-Warfarin.

4-hydroxycoumarin

Moderate

The risk or severity of bleeding can be increased when Acetic acid is combined with 4-hydroxycoumarin.

Vosol Hc Toxicity & Overdose Risk

Taking too much glucocorticoid medication can cause long-term issues such as cataracts, glaucoma, high blood pressure, water retention, and lipids in the blood. It can also cause ulcers, pancreatitis, muscle weakness, changes in mood or behavior, skin thinning, allergies, acne, increased hair growth, decreased immunity, a round face, high blood sugar, low calcium or phosphorus levels, and slowed growth in children. To treat an overdose, the dose may need to be adjusted or stopped and other treatments may be necessary.

image of a doctor in a lab doing drug, clinical research

Vosol Hc Novel Uses: Which Conditions Have a Clinical Trial Featuring Vosol Hc?

Currently, there are 525 active clinical trials investigating the potential of Vosol Hc for alleviating Ulcerative Colitis, Inflammation and Trichinosis.

Condition

Clinical Trials

Trial Phases

Urinary Bladder

0 Actively Recruiting

Otitis Externa

0 Actively Recruiting

Infection

6 Actively Recruiting

Not Applicable, Phase 1

Communicable Diseases

0 Actively Recruiting

Urethral Catheters

0 Actively Recruiting

Vosol Hc Reviews: What are patients saying about Vosol Hc?

5

Patient Review

4/1/2013

Vosol Hc for Inflammation of the External Ear Resembling Eczema

It's only been three days, but I've already seen a world of difference. My ENT said that I have a fungal infection, as well as some possible eczema. But more importantly, the incessant itching and drainage has stopped! Finally able to live my life again.

1.7

Patient Review

12/28/2013

Vosol Hc for Inflammation of the External Ear Resembling Eczema

Did not provide any relief for the severe itching I was experiencing in both ears.

Patient Q&A Section about vosol hc

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I need a prescription for acetic acid ear drops?

"This medicine is used to treat the symptoms of bacterial or fungal infections in the ear. It may be used alone or with other medications."

Answered by AI

Is Vosol a prescription?

"If you experience burning or stinging in your ear canal, let your doctor or pharmacist know. while this side effect is only temporary, it can worsen over time. Keep in mind that your doctor prescribed this medication because they believe the benefits outweigh the risks of side effects."

Answered by AI

What is Vosol HC used for?

"This combination medication is designed to treat outer ear infection (such as swimmer's ear). Acetic acid, one of the two medications, works to stop the growth of bacteria and fungus. The other medication, hydrocortisone, is a steroid that helps reduce the redness, swelling, and itching that come with the infection."

Answered by AI

How long should you use acetic acid ear drops?

"Use 3-5 drops of hydrocortisone and acetic acid in the affected ear every 4-6 hours for the first 24 hours, then use 5 drops 3-4 times daily."

Answered by AI

Clinical Trials for Vosol Hc

Image of National Institutes of Health Clinical Center in Bethesda, United States.

gp91 Grans for Chronic Granulomatous Disease

18 - 75
Male
Bethesda, MD

Background: CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells. Objective: To test a procedure in which mRNA is added to a person s blood cells. Eligibility: Males aged 18-75 with CGD with a mutation in the gene that makes the protein gp91phox. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Swab to test for strep throat Some screening tests will be repeated during the study. Participants will be admitted to the NIH Clinical Center hospital for at least 7 days. They will have apheresis. For this, a medicine is injected under their skin to prepare their white blood cells for collection. An IV line is placed into an arm vein. Blood goes through the IV line into a machine that divides whole blood into red blood cells, plasma, and white blood cells. The white blood cells are removed, and the rest of the blood is returned to the participant through an IV line in their other arm. The next day, they will get their mRNA-corrected cells via IV. They will be monitored for 3 more days. After discharge, participants will keep a symptom diary. They will be contacted weekly for one month, and then once a month. They will have a follow-up visit 3 months after the infusion.

Phase 1
Recruiting

National Institutes of Health Clinical Center

Suk S De Ravin, M.D.

Image of University of Connecticut in Farmington, United States.

Prostate Biopsy Techniques for Reducing Infection Risk

18+
Male
Farmington, CT

Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer. This randomized controlled trial will be the first prospective study to evaluate in-office transperineal MRI targeted prostate biopsy. The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.

Recruiting
Has No Placebo

University of Connecticut (+16 Sites)

Jim C Hu, MD MPH

Image of University of Iowa in Iowa City, United States.

Improved Perioperative Preventive Measures for Surgical Site Infections

18+
All Sexes
Iowa City, IA

Surgical site infections (SSIs) are associated with increased patient morbidity, mortality, and healthcare costs. ESKAPE (Enterococcus, S. aureus, Klebsiella, Acinetobacter, Pseudomonas, and Enterobacter spp.) pathogens are particularly pathogenic because they have increased capacity to acquire resistance and virulence traits. The investigators have proven that a multifaceted program involving improved basic perioperative preventive measures can generate substantial reductions in S. aureus transmission and significant reductions in SSIs (88% reduction as compared to usual care). In this study, the investigators aim to examine the relative effectiveness of each component of this program in controlling ESKAPE transmission and reducing SSIs and to identify an optimal implementation strategy for national dissemination. Randomization occurs at the site level, and sites adopt preventative programs. This work will improve perioperative patient safety for the 51 million patients who undergo surgery each year.

Recruiting
Has No Placebo

University of Iowa (+2 Sites)

Jeremiah R Brown, PhD

Have you considered Vosol Hc clinical trials?

We made a collection of clinical trials featuring Vosol Hc, we think they might fit your search criteria.
Go to Trials